Drugs in Phase II clinical trials for the treatment of age-related macular degeneration

Bibliography

• World Health Organization. Priority eye diseases. 2014. Available from: http://www.who.int/blindness/causes/priority [Cited 2014]
   Google Scholar
• Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122(4):564-72
   PubMed Web of Science ®Google Scholar
• Beatty S, Murray IJ, Henson DB, et al. Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci 2001;42(2):439-46
   PubMed Web of Science ®Google Scholar
• Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996;276(14):1141-6
   PubMed Web of Science ®Google Scholar
• Margrain TH, Boulton M, Marshall J, Sliney DH. Do blue light filters confer protection against age-related macular degeneration? Prog Retin Eye Res 2004;23(5):523-31
   PubMed Web of Science ®Google Scholar
• Taylor HR, West S, Munoz B, et al. The long-term effects of visible light on the eye. Arch Ophthalmol 1992;110(1):99-104
   PubMed Web of Science ®Google Scholar
• Pauleikhoff D, Barondes MJ, Minassian D, et al. Drusen as risk factors in age-related macular disease. Am J Ophthalmol 1990;109(1):38-43
   PubMed Web of Science ®Google Scholar
• Hageman GS, Mullins RF. Molecular composition of drusen as related to substructural phenotype. Mol Vis 1999;5:28
   PubMed Web of Science ®Google Scholar
• Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 2010;29(2):95-112
   PubMed Web of Science ®Google Scholar
• Barouch FC, Miller JW. The role of inflammation and infection in age-related macular degeneration. Int Ophthalmol Clin 2007;47(2):185-97
   PubMedGoogle Scholar
• Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001;20(6):705-32
   PubMed Web of Science ®Google Scholar
• Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134(3):411-31
   PubMed Web of Science ®Google Scholar
• Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2013;120(1):106-14
   PubMed Web of Science ®Google Scholar
• Edwards AO, Ritter RIII, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308(5720):421-4
   PubMed Web of Science ®Google Scholar
• Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005;102(20):7227-32
   PubMed Web of Science ®Google Scholar
• Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308(5720):419-21
   PubMed Web of Science ®Google Scholar
• Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308(5720):385-9
   PubMed Web of Science ®Google Scholar
• Zareparsi S BK, Li M, Shah S, et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet 2005;77(1):149-53
   PubMed Web of Science ®Google Scholar
• Lommatzsch A, Hermans P, Müller KD, et al. Are low inflammatory reactions involved in exudative age-related macular degeneration? Morphological and immunhistochemical analysis of AMD associated with basal deposits. Graefes Arch Clin Exp Ophthalmol 2008;246(6):803-10
   PubMed Web of Science ®Google Scholar
• Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci USA 2002;12(99):14682-7
   Google Scholar
• Heinen S, Hartmann A, Lauer N, et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009;114(12):2439-47
   PubMed Web of Science ®Google Scholar
• Józsi M, Zipfel PF. Factor H family proteins and human diseases. Trends Immunol 2008;29(8):380-7
   PubMed Web of Science ®Google Scholar
• Raychaudhuri S, Ripke S, Li M, et al. Associations of CFHR1-CFHR3 deletion and a CFH SNP to age-related macular degeneration are not independent. Nat Genet 2010;42(7):553-5
   PubMed Web of Science ®Google Scholar
• Lamb LE, Simon JD. A2E: a component of ocular lipofuscin. Photochem Photobiol 2004;79(2):127-36
   PubMed Web of Science ®Google Scholar
• Bearelly S, Khanifar AA, Lederer DE, et al. Use of fundus autofluorescence images to predict geographic atrophy progression. Retina 2011;31(1):81-6
   PubMed Web of Science ®Google Scholar
• Davies S, Elliott MH, Floor E, et al. Photocytotoxicity of lipofuscin in human retinal pigment epithelial cells. Free Radic Biol Med 2001;31(2):256-65
   PubMed Web of Science ®Google Scholar
• Dorey CK, Wu G, Ebenstein D, et al. Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration. Invest Ophthalmol Vis Sci 1989;30(8):1691-9
   PubMed Web of Science ®Google Scholar
• Sparrow JR, Nakanishi K, Parish CA. The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. Invest Ophthalmol Vis Sci 2000;41(7):1981-9
   PubMed Web of Science ®Google Scholar
• Vives-Bauza C, Anand M, Shiraz AK, et al. The age lipid A2E and mitochondrial dysfunction synergistically impair phagocytosis by retinal pigment epithelial cells. J Biol Chem 2008;283(36):24770-80
   PubMed Web of Science ®Google Scholar
• van der Burght BW, Hansen M, Olsen J, et al. Early changes in gene expression induced by blue light irradiation of A2E-laden retinal pigment epithelial cells. Acta Ophthalmol (Copenh) 2013;91(7):e537-45
   Google Scholar
• Murdaugh LS, Mandal S, Dill AE, et al. Compositional studies of human RPE lipofuscin: mechanisms of molecular modifications. J Mass Spectrom 2011;46(1):90-5
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119(10):1417-36
   PubMed Web of Science ®Google Scholar
• Chew EY, Clemons TE, Agron E, et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology 2013;120(8):1604-11. e4
   PubMed Web of Science ®Google Scholar
• Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309(19):2005-15
   PubMed Web of Science ®Google Scholar
• Awh CC, Lane AM, Hawken S, et al. CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 2013;120(11):2317-23
   PubMed Web of Science ®Google Scholar
• Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996;98(7):1667-75
   PubMed Web of Science ®Google Scholar
• Bora NS, Kaliappan S, Jha P, et al. Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. J Immunol 2006;177(3):1872-8
   PubMed Web of Science ®Google Scholar
• Bora PS, Sohn JH, Cruz JM, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol 2005;174(1):491-7
   PubMed Web of Science ®Google Scholar
• Tolentino MJ. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. Curr Mol Med 2009;9(8):973-81
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65
   PubMed Web of Science ®Google Scholar
• IVAN Study Investigators. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119(7):1399-411
   PubMed Web of Science ®Google Scholar
• CATT Research Group. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-908
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119(7):1388-98
   PubMed Web of Science ®Google Scholar
• Kaiser PK. Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline. Ophthalmology 2013;120(5):S11-15
   PubMed Web of Science ®Google Scholar
• Friberg TR, Tolentino M, Weber P, et al. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol 2010;94(12):1611-17
   PubMed Web of Science ®Google Scholar
• Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56(2):95-113
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-908
   PubMed Web of Science ®Google Scholar
• Jansen RM. The off-label use of medication: the latest on the Avastin - Lucentis debacle. Med Law 2013;32(1):65-77
   PubMedGoogle Scholar
• Nunes RP, Rosenfeld PJ, de Amorim Garcia Filho CA, et al. Age related macular degeneration ophthalmology. 4 edition. Saunders, An Imprint of Elsevier; 2013. p. 580-98
   Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26(8):859-70
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31
   PubMed Web of Science ®Google Scholar
• Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2009;18(10):1573-80
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119(12):2537-48
   PubMed Web of Science ®Google Scholar
• Borras L, Gunde T, Tietz J, et al. Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies. J Biol Chem 2010;285(12):9054-66
   PubMed Web of Science ®Google Scholar
• Wu Z, Zhou P, Li X, et al. Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling. PLoS One 2013;8(3):e57642
   PubMed Web of Science ®Google Scholar
• Wang Q, Li T, Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo. PLoS One 2013;8(8):e70544
   PubMed Web of Science ®Google Scholar
• Binz HK, Amstutz P, Kohl A, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 2004;22(5):575-82
   PubMed Web of Science ®Google Scholar
• Binz HK, Stumpp MT, Forrer P, et al. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 2003;332(2):489-503
   PubMed Web of Science ®Google Scholar
• Stumpp MT BH, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discov Today 2008;13(15-16):695-701
   PubMed Web of Science ®Google Scholar
• Stahl A, Stumpp MT, Schlegel A, et al. Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis 2013;16(1):101-11
   PubMed Web of Science ®Google Scholar
• Arons I. AMD update 24: darpins Phase 2 trial reslts fall short. Irv Arons Journal 2013
   Google Scholar
• McLaughlin MM, Paglione MG, Slakter J, et al. Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration. JAMA Ophthalmol 2013;131(12):1595-601
   PubMed Web of Science ®Google Scholar
• Thakur A, Scheinman RI, Rao VR, Kompella UB. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res 2011;82(3):346-50
   PubMed Web of Science ®Google Scholar
• Danis R, McLaughlin MM, Tolentino M, Pazopanib Eye Drops Study Group. Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration. Br J Ophthalmol 2014;98(2):172-8
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6(7):2012-21
   PubMed Web of Science ®Google Scholar
• Kernt M, Thiele S, Neubauer AS, et al. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. Retina 2012;32(8):1652-63
   PubMed Web of Science ®Google Scholar
• Csaky C. A phase 2b dose-ranging study of pazopanib eye drops vs. ranibizumab intravitreal injections for the treatment of neovascular AMD. Retina Subspecialty Conference (AAO) 2013; 15 November 2013; New Orleans, LA
   Google Scholar
• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129(1):245-55
   PubMed Web of Science ®Google Scholar
• Auricchio A, Behling KC, Maguire AM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther 2002;6(4):490-4
   PubMed Web of Science ®Google Scholar
• Igarashi T, Miyake K, Masuda I, et al. Adeno-associated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model. Hum Gene Ther 2010;21(5):631-7
   PubMed Web of Science ®Google Scholar
• Dalkara D, Byrne LC, Klimczak RR, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013;5(189):189ra76
   PubMed Web of Science ®Google Scholar
• Choudhury P, Chen W, Hunt RC. Production of platelet-derived growth factor by interleukin-1 beta and transforming growth factor-beta-stimulated retinal pigment epithelial cells leads to contraction of collagen gels. Invest Ophthalmol Vis Sci 1997;38(5):824-33
   PubMed Web of Science ®Google Scholar
• Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168(6):2036-53
   PubMed Web of Science ®Google Scholar
• Šmuc T, Ahn IY, Ulrich H. Nucleic acid aptamers as high affinity ligands in biotechnology and biosensorics. J Pharm Biomed Anal 2013;81-82:210-17
   PubMed Web of Science ®Google Scholar
• Mayer G, Jenne A. Aptamers in research and drug development. BioDrugs 2004;18(6):351-9
   PubMed Web of Science ®Google Scholar
• Dugel P. Phase 2b clinical trial of Fovista anti-PDGF therapy (1.5 mg) in patients with neovascular age-related macular degeneration (wet AMD). Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO); 10 November 2012; Chicago
   Google Scholar
• Corradetti MN, Inoki K, Guan KL. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem 2005;280(11):9769-72
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Schachar RA, Nduaka CI, et al. Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (Lond) 2012;26(8):1099-105
   PubMed Web of Science ®Google Scholar
• Brafman A, Mett I, Shafir M, et al. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest Ophthalmol Vis Sci 2004;45(10):3796-805
   PubMed Web of Science ®Google Scholar
• Shoshani T, Faerman A, Mett I, et al. Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, RTP801, Involved in Apoptosis. Mol Cell Biol 2002;22(7):2283-93
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Schachar RA, Nduaka CI, MONET Clinical Study Group. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology 2012;119(9):1867-73
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8(2):129-38
   PubMed Web of Science ®Google Scholar
• Caballero S, Swaney J, Moreno K, et al. Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp Eye Res 2009;88(3):367-77
   PubMed Web of Science ®Google Scholar
• Xie B, Shen J, Dong A, et al. Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J Cell Physiol 2009;218(1):192-8
   PubMed Web of Science ®Google Scholar
• Connolly B, Desai A, Garcia CA, et al. Squalamine lactate for exudative age-related macular degeneration. Ophthalmol Clin North Am 2006;19(3):381-91, vi
   PubMedGoogle Scholar
• Cao X, Shen D, Patel MM, et al. Macrophage polarization in the maculae of age-related macular degeneration: a pilot study. Pathol Int 2011;61(9):528-35
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011;118(3):523-30
   PubMed Web of Science ®Google Scholar
• Castano AP, Lin SL, Surowy T, et al. Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 2009;1(5):5ra13
   PubMed Web of Science ®Google Scholar
• Duffield JS, Lupher M, Thannickal VJ, Wynn TA. Host responses in tissue repair and fibrosis. Annu Rev Pathol 2013;8:241-76
   PubMed Web of Science ®Google Scholar
• Dillingh MR, van den Blink B, Moerland M, et al. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther 2013;26(6):672-6
   PubMed Web of Science ®Google Scholar
• Krebs I, Brannath W, Glittenberg C, et al. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 2007;144(5):741-6
   PubMed Web of Science ®Google Scholar
• Mojana F, Cheng L, Bartsch DU, et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol 2008;146(2):218-27
   PubMed Web of Science ®Google Scholar
• de Smet MD, Valmaggia C, Zarranz-Ventura J, Willekens B. Microplasmin: ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci 2009;50(2):814-19
   PubMed Web of Science ®Google Scholar
• Gandorfer A, Rohleder M, Sethi C, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 2004;45(2):641-7
   PubMed Web of Science ®Google Scholar
• Tsui I, Pan CK, Rahimy E, Schwartz SD. Ocriplasmin for vitreoretinal diseases. J Biomed Biotechnol 2012;2012:354979
   PubMedGoogle Scholar
• Xu Y, Narayana SV, Volanakis JE. Structural biology of the alternative pathway convertase. Immunol Rev 2001;180:123-35
   PubMed Web of Science ®Google Scholar
• Reynolds R, Hartnett ME, Atkinson JP, et al. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 2009;50(12):5818-27
   PubMed Web of Science ®Google Scholar
• Hecker LA, Edwards AO, Ryu E, et al. Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet 2010;19(1):209-15
   PubMed Web of Science ®Google Scholar
• Loyet KM, Deforge LE, Katschke KJJr, et al. Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration. Invest Ophthalmol Vis Sci 2012;53(10):6628-37
   PubMed Web of Science ®Google Scholar
• Stanton CM, Yates JR, den Hollander AI, et al. Complement factor D in age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52(12):8828-34
   PubMed Web of Science ®Google Scholar
• Katschke KJJr, Wu P, Ganesan R, et al. Inhibiting alternative pathway complement activation by targeting the factor D exosite. J Biol Chem 2012;287(16):12886-92
   PubMed Web of Science ®Google Scholar
• Williams D. Lampalizumab (anti-factor D) in geographic atrophy: the MAHALO phase II results. American Society of Retina Specialists (ASRS) 31st Annual Meeting; 27 August 2013; Toronto, Ontario, Canada
   Google Scholar
• Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 2006;103(7):2328-33
   PubMed Web of Science ®Google Scholar
• Baas DC, Ho L, Ennis S, et al. The complement component 5 gene and age-related macular degeneration. Ophthalmology 2010;117(3):500-11
   PubMed Web of Science ®Google Scholar
• Yehoshua Z, Alexandre de Amorim Garcia Filho C, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE Study. Ophthalmology 2014;121(3):693-701
   PubMed Web of Science ®Google Scholar
• Dentchev T, Milam AH, Lee VM, et al. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 2003;14(9):184-90
   Google Scholar
• Johnson LV, Leitner WP, Rivest AJ, et al. The Alzheimer’s A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 2002;99(18):11830-5
   PubMed Web of Science ®Google Scholar
• Anderson DH, Talaga KC, Rivest AJ, et al. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 2004;78(2):243-56
   PubMed Web of Science ®Google Scholar
• Ding JD, Johnson LV, Herrmann R, et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci USA 2011;108(28):E279-87
   PubMed Web of Science ®Google Scholar
• Damico FM, Gasparin F, Scolari MR, et al. New approaches and potential treatments for dry age-related macular degeneration. Arg Bras Oftalmol 2012;75(1):71-6
   PubMed Web of Science ®Google Scholar
• Kawaguchi R, Yu J, Honda J, et al. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science 2007;315(5813):820-5
   PubMed Web of Science ®Google Scholar
• Baglietto L, Torrisi R, Arena G, et al. Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer. Cancer Detect Prev 2000;24(4):369-75
   PubMedGoogle Scholar
• Maeda A, Maeda T, Golczak M, et al. Effects of potent inhibitors of the retinoid cycle on visual function and photoreceptor protection from light damage in mice. Mol Pharmacol 2006;70(4):1220-9
   PubMed Web of Science ®Google Scholar
• Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina 2013;33(3):498-507
   PubMed Web of Science ®Google Scholar
• Quadro L, Blaner WS, Hamberger L, et al. The role of extrahepatic retinol binding protein in the mobilization of retinoid stores. J Lipid Res 2004;45(11):1975-82
   PubMed Web of Science ®Google Scholar
• Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina 2013;33(3):498-507
   PubMed Web of Science ®Google Scholar
• Kubota R, Al-Fayoumi S, Mallikaarjun S, et al. Phase 1, dose-ranging study of emixustat hydrochloride (acu-4429), a novel visual cycle modulator, in healthy volunteers. Retina 2014;34(3):603-9
   PubMed Web of Science ®Google Scholar
• Meagher KA, Thurnham DI, Beatty S, et al. Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration. Br J Nutr 2013;110(2):289-300
   PubMed Web of Science ®Google Scholar
• Li B, Ahmed F, Bernstein PS. Studies on the singlet oxygen scavenging mechanism of human macular pigment. Arch Biochem Biophys 2010;504(1):56-60
   PubMed Web of Science ®Google Scholar
• Akuffo KO, Beatty S, Stack J, et al. Central Retinal Enrichment Supplementation Trials (CREST): design and methodology of the CREST randomized controlled trials. Ophthalmic Epidemiol 2014;21(2):111-23
   PubMed Web of Science ®Google Scholar
• Thurnham DI, Howard AN. Studies on meso-zeaxanthin for potential toxicity and mutagenicity. Food Chem Toxicol 2013;59:455-63
   PubMed Web of Science ®Google Scholar